scholarly journals Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis

2020 ◽  
Vol 9 (1) ◽  
Author(s):  
Yuxi Li ◽  
Xiaobo Liu ◽  
Liuxue Guo ◽  
Juan Li ◽  
Dongling Zhong ◽  
...  
Keyword(s):  
Systematic Review ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Meta Analysis ◽  
Traditional Chinese Herbal Medicine ◽  
Chinese Herbal ◽  
Novel Coronavirus

scholarly journals Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis

2020 ◽  
Author(s):  
Yuxi Li ◽  
Xiaobo Liu ◽  
Liuxue Guo ◽  
Juan Li ◽  
Dongling Zhong ◽  
...  
Keyword(s):  
Systematic Review ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Meta Analysis ◽  
Biomedical Literature ◽  
World Health ◽  
Cochrane Central Register ◽  
Traditional Chinese Herbal Medicine ◽  
Chinese Herbal ◽  
Novel Coronavirus

Abstract Background A new type of coronavirus, novel coronavirus (COVID-19), is causing an increasing number of cases of pneumonia and was declared a Public Health Emergency of International Concern by the World Health Organization on 30 January 2020. The virus first appeared in Wuhan, China in late December 2019 and traditional Chinese herbal medicine is being used for its treatment. This systematic review and meta-analysis will assess studies of the effects of traditional Chinese herbal medicine in COVID-19 pneumonia. Methods We will search electronic databases including PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Periodical Database (VIP) and Wanfang database using keywords related to COVID-19 and traditional Chinese herbal medicine. Reference lists of relevant trials and reviews will be searched. We will manually search grey literature, such as conference proceedings and academic degree dissertations, and trial registries. Two independent reviewers will screen studies (XL and DZ), extract data (YL and LG) and evaluate risk of bias (YL and DZ). Data analysis will be conducted using Review Manager software (version 5.3.5) and R software (version 3.6.1). Statistical heterogeneity will be assessed using a standard Chi-square test with a significance level of P < 0.10. Biases associated with study size (e.g. publication bias) will be investigated using funnel plots, the Egger 's test and Begg 's test and Trim and Fill analysis. Discussion This study will provide a high-quality synthesis of the effects of traditional Chinese herbal medicine for COVID-19. The use of traditional Chinese herbal medicine for treatment or prevention of these novel viral infections affecting the pneumonia will be investigated. Systematic review registration PROSPERO registration number: CRD42020168004

scholarly journals Clinical Practice Guidelines of Traditional Chinese Herbal Medicine for Novel Coronavirus (Covid-19): Protocol of a Systematic Review

2020 ◽  
Author(s):  
Yuxi Li ◽  
Juan Li ◽  
Dongling Zhong ◽  
Yue Zhang ◽  
Yonggang Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Practice ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Practice Guidelines ◽  
Agree Ii ◽  
Traditional Chinese Herbal Medicine ◽  
Chinese Herbal ◽  
Novel Coronavirus

Abstract Background: The World Health Organization declared on 11 March 2020 that thespread of the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) had escalated from epidemic into pandemic. As the initial outbreak area, China has taken multiple active measures to deal with the epidemic. Updated versions of diagnosis and treatment guideline for novel coronavirus (COVID-19)patients have been issued, and traditional Chinese herbal medicine has been recommended as a treatment.Methods: In this systematic review, we will search for guidelines, expert consensuses and policy documents published since December 2019 in electronic databases and on websites of governments or organizations. Eligible documents will be independently selected, and relevant data will be independently extracted by two reviewers. We will also independently evaluate the methodological quality and reporting quality of the included guidelines, using the Appraisal of Guidelines for REsearch& Evaluation (AGREE) II tool and Reporting Items for Practice Guidelines in healthcare (RIGHT) statement, respectively. Any discrepancies will be discussed and resolved through discussion among the reviewers. We will use the extracted information to summarize their recommendationsfor traditional Chinese herbal formulae and Chinese patent medicine for COVID-19 patients, and to summarize the strength and quality of these recommendations with reference to the findings from the AGREE II and RIGHT tools.Discussion: This review will summarize the recommendations in current clinical practice guidelines andprovide insight into the implementation strategies for traditional Chinese herbal medicine in COVID-19 patients. Systematic review registration: PROSPERO registration number: CRD42020179205

scholarly journals Chinese Herbal Medicine (“3 Medicines and 3 Formulations”) for COVID-19: Rapid Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Xiao-Yang Hu ◽  
Yangzihan Wang ◽  
Junqiao Chen ◽  
Trisha Greenhalgh ◽  
Jon Wardle
Keyword(s):  
Systematic Review ◽  
Herbal Medicine ◽  
Disease Severity ◽  
Chinese Herbal Medicine ◽  
English Language ◽  
Meta Analysis ◽  
Chinese Herbal ◽  
Clinical Trial Registries ◽  
Inverse Variance ◽  
Secondary Outcomes

Abstract Background: To evaluate the evidence behind claims that Chinese Herbal Medicine, specifically “three medicines and three formulations” (3M3F, comprising Jinhua Qinggan, Lianhua Qingwen, Xuebijing, Qingfei Paidu, Huashi Baidu and Xuanfei Baidu), is an effective treatment for COVID-19. Methods: We searched PubMed, MEDLINE and CNKI databases, preprint servers, clinical trial registries and supplementary sources for Chinese- or English-language randomised trials or non-randomised studies with comparator groups, which tested the constituents of 3M3F in the treatment of COVID-19 up to September 2020. Primary outcome was change in disease severity. Secondary outcomes included various symptoms. Meta-analysis (using generic inverse variance random effects model) was performed when there were two or more studies reporting on the same symptom. Results: Of 607 articles identified, thirteen primary studies (six RCTs and seven retrospective non-randomised comparative studies) with 1467 participants met our final inclusion criteria. Studies were small and had significant methodological limitations, most notably potential bias in assessment of outcomes. No study convincingly demonstrated a statistically significant impact on change in disease severity. Eight studies reported sufficiently similar secondary outcomes to be included in a meta-analysis. Some statistically significant impacts on symptoms, chest CT manifestations, laboratory variables and length of stay were demonstrated, but such findings were sparse and many remain unreplicated.Conclusions: These findings neither support nor refute the claim that 3M3F alters the severity of COVID-19 or alleviates symptoms. More rigorous studies are required to properly ascertain the potential role of Chinese Herbal Medicine in COVID-19.Systematic review registration: This review was registered on PROSPERO (CRD42020187502) prior to data collection and analysis.

Sign in / Sign up

Export Citation Format

Share Document